Jiali Wang1, Changyu Jiang2, Xiyuan Ba2, Shimin Yang1, Jiaman Wu1, Zelin Huang1, Guangyi Jin3, Yue Hao4. 1. School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, 518060, People's Republic of China. 2. Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, Shenzhen Nanshan People's Hospital and the 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, People's Republic of China. 3. School of Pharmaceutical Sciences, Nation-regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, Shenzhen University Health Science Center, Shenzhen, People's Republic of China. 4. School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, 518060, People's Republic of China. yuehao@szu.edu.cn.
Abstract
RATIONALE: Paclitaxel-induced acute pain syndrome (P-APS), characterized by deep muscle aches and arthralgia, occurs in more than 70% of patients who receive paclitaxel. P-APS can be debilitating for patients and lead to reductions and discontinuation of potentially curable therapy. Despite being relatively common in clinical practice, no clear treatment exists for P-APS and the underlying mechanisms remain poorly defined. Regulation of glutamatergic transmission by metabotropic glutamate receptors (mGluRs) has received growing attention with respect to its role in neuropathic pain. To our knowledge, no study has been conducted on alterations and functions of group III mGluR7 signaling in P-APS. OBJECTIVES: In the present study, we determined whether a single administration of paclitaxel induces glutamatergic alterations and whether mGluR7 activation blocks paclitaxel-induced neuropathic pain by suppressing glial reactivity in the spinal cord. RESULTS: A single paclitaxel injection dose-dependently induced acute mechanical and thermal hypersensitivity, and was associated with increased glutamate level accompanied by reduction in mGluR7 expression in the spinal cord. Selective activation of mGluR7 by its positive allosteric modulator, AMN082, blocked the development of paclitaxel-induced acute mechanical and thermal hypersensitivity, without affecting the normal pain behavior of control rats. Moreover, activation of mGluR7 by AMN082 inhibited glial reactivity and decreased pro-inflammatory cytokine release during P-APS. Abortion of spinal glial reaction to paclitaxel alleviated paclitaxel-induced acute mechanical and thermal hypersensitivity. CONCLUSIONS: There results support the hypothesis that spinal mGluR7 signaling plays an important role in P-APS; Selective activation of mGluR7 by its positive allosteric modulator, AMN082, blocks P-APS in part by reducing spinal glial reactivity and neuroinflammatory process.
RATIONALE: Paclitaxel-induced acute pain syndrome (P-APS), characterized by deep muscle aches and arthralgia, occurs in more than 70% of patients who receive paclitaxel. P-APS can be debilitating for patients and lead to reductions and discontinuation of potentially curable therapy. Despite being relatively common in clinical practice, no clear treatment exists for P-APS and the underlying mechanisms remain poorly defined. Regulation of glutamatergic transmission by metabotropic glutamate receptors (mGluRs) has received growing attention with respect to its role in neuropathic pain. To our knowledge, no study has been conducted on alterations and functions of group III mGluR7 signaling in P-APS. OBJECTIVES: In the present study, we determined whether a single administration of paclitaxel induces glutamatergic alterations and whether mGluR7 activation blocks paclitaxel-induced neuropathic pain by suppressing glial reactivity in the spinal cord. RESULTS: A single paclitaxel injection dose-dependently induced acute mechanical and thermal hypersensitivity, and was associated with increased glutamate level accompanied by reduction in mGluR7 expression in the spinal cord. Selective activation of mGluR7 by its positive allosteric modulator, AMN082, blocked the development of paclitaxel-induced acute mechanical and thermal hypersensitivity, without affecting the normal pain behavior of control rats. Moreover, activation of mGluR7 by AMN082 inhibited glial reactivity and decreased pro-inflammatory cytokine release during P-APS. Abortion of spinal glial reaction to paclitaxel alleviated paclitaxel-induced acute mechanical and thermal hypersensitivity. CONCLUSIONS: There results support the hypothesis that spinal mGluR7 signaling plays an important role in P-APS; Selective activation of mGluR7 by its positive allosteric modulator, AMN082, blocks P-APS in part by reducing spinal glial reactivity and neuroinflammatory process.
Authors: V Chaparro-Huerta; M C Rivera-Cervantes; M E Flores-Soto; U Gómez-Pinedo; C Beas-Zárate Journal: J Neuroimmunol Date: 2005-08 Impact factor: 3.478
Authors: Elisa Burgos; Diego Gómez-Nicola; David Pascual; María Isabel Martín; Manuel Nieto-Sampedro; Carlos Goicoechea Journal: Eur J Pharmacol Date: 2012-02-21 Impact factor: 4.432
Authors: V A Carozzi; A Canta; N Oggioni; B Sala; A Chiorazzi; C Meregalli; M Bossi; P Marmiroli; G Cavaletti Journal: Exp Neurol Date: 2010-09-09 Impact factor: 5.330
Authors: Beatriz de la Puente; Xavier Nadal; Enrique Portillo-Salido; Ricard Sánchez-Arroyos; Sergio Ovalle; Gabriel Palacios; Asunción Muro; Luz Romero; José Manuel Entrena; José Manuel Baeyens; José Antonio López-García; Rafael Maldonado; Daniel Zamanillo; José Miguel Vela Journal: Pain Date: 2009-06-07 Impact factor: 6.961
Authors: Sergio M Borghi; Victor Fattori; Felipe A Pinho-Ribeiro; Talita P Domiciano; Milena M Miranda-Sapla; Tiago H Zaninelli; Rubia Casagrande; Phileno Pinge-Filho; Wander R Pavanelli; Jose C Alves-Filho; Fernando Q Cunha; Thiago M Cunha; Waldiceu A Verri Journal: J Neuroinflammation Date: 2019-05-28 Impact factor: 8.322